Literature DB >> 4003031

Vibratory perception threshold compared with nerve conduction velocity in the evaluation of uremic neuropathy.

R Tegnér, B Lindholm.   

Abstract

Clinical signs of neuropathy, vibratory perception thresholds, nerve conduction velocities, and distal motor latencies were compared in 81 patients with chronic renal failure. During treatment with low protein diets (LPD), the vibratory thresholds correlated better with the clinical grading of the neuropathy than did the conduction velocities or the distal motor latencies, while during hemodialysis (HD), the situation was the reverse. The vibratory threshold on the foot was the single most useful test, since it correlated with the clinical grading of the neuropathy both during LPD and HD, and both between and within patients.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4003031     DOI: 10.1111/j.1600-0404.1985.tb03201.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  4 in total

1.  Quantitative sensory testing of thermal and vibratory perception in familial dysautonomia.

Authors:  M J Hilz; F B Axelrod
Journal:  Clin Auton Res       Date:  2000-08       Impact factor: 4.435

2.  Vibratory perception thresholds at the clavicle in patients with spinal cord injury.

Authors:  I Herszkowicz; A Berić; U Lindblom
Journal:  J Neurol Neurosurg Psychiatry       Date:  1986-09       Impact factor: 10.154

3.  Peripheral nerve function in children with end-stage renal failure.

Authors:  C E de Beaufort; J L André; J J Heimans; H A van der Eerden; N G van Diemen; M L Duc; M Pierson
Journal:  Pediatr Nephrol       Date:  1989-04       Impact factor: 3.714

Review 4.  Early diagnosis of peripheral nervous system involvement in Fabry disease and treatment of neuropathic pain: the report of an expert panel.

Authors:  Alessandro P Burlina; Katherine B Sims; Juan M Politei; Gary J Bennett; Ralf Baron; Claudia Sommer; Anette Torvin Møller; Max J Hilz
Journal:  BMC Neurol       Date:  2011-05-27       Impact factor: 2.474

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.